Identification

Name
Nitroglycerin
Accession Number
DB00727
Description

Nitroglycerin is a vasodilator drug used for the treatment of chest pain and high blood pressure.12,13 It was first approved in 2000 and is currently marketed by Pfizer, and other companies, depending on the dosage form.12,15 Nitroglycerin is available in various forms, including a spray form, sublingual tablet form, intravenous form, extended-release tablet form, and transdermal form. A less commonly known fact is that in addition to treating angina, nitroglycerin is also used in an ointment to treat the pain that accompanies anal fissures. The rectal ointment form of nitroglycerin was approved by the FDA in 1955.14

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 227.0865
Monoisotopic: 227.002578773
Chemical Formula
C3H5N3O9
Synonyms
  • 1,2,3-propanetrioltrinitrate
  • 1,2,3-propanetriyl nitrate
  • Glycerin trinitrate
  • Glycerol trinitrate
  • Glycerol, nitric acid triester
  • Glyceroli trinitratis
  • Glyceroltrinitrat
  • Glyceryl trinitrate
  • NG
  • Nitroglicerina
  • Nitroglycerin
  • Nitroglycerine
  • Nitroglycerol
  • Nitromed
  • Propane-1,2,3-triyl trinitrate
  • Trinitrine
  • Trinitroglycerin
  • Trinitroglycerol
External IDs
  • DR 66
  • IMX-150

Pharmacology

Indication

Nitroglycerin is indicated for various purposes.15 It is indicated to prevent and treat angina or chest pain due to cardiovascular disease, as well as to treat peri-operative hypertension or induce intra-operative hypotension.13,16 It is also indicated to treat acute heart failure in patients with myocardial infarction.16 In the ointment form, nitroglycerin is indicated to treat pain caused by anal fissures.14 The transdermal form is applied directly to the skin to prevent acute anginal attacks.20

The intravenous form is used off-label in emergency settings and is commonly used to treat acute coronary spasm caused by cocaine, hypertensive emergencies, as well as acute congestive heart failure exacerbations.12 Some other off-label uses of nitroglycerin include management of variceal hemorrhage10, management of esophageal spasticity11, and induction of uterine relaxation.9

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Nitroglycerin causes the relaxation of vascular smooth muscles, causing arteriolar and venous dilatation. It reduces cardiac preload and afterload and reduces coronary artery spasm, decreasing systemic vascular resistance as well as systolic and diastolic blood pressure.13 The reduction of cardiac work by nitroglycerin is thought to cause the most relief of anginal symptoms, with some contributions from arteriolar dilatation effects.12

Mechanism of action

Nitroglycerin is converted by mitochondrial aldehyde dehydrogenase (mtALDH) to nitric oxide (NO), an active substance which then activates the enzyme guanylate cyclase.2 The activation of this enzyme is followed by the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP), activating a cascade of protein kinase-dependent phosphorylation events in smooth muscles. This process eventually leads to the dephosphorylation of the myosin light chain of smooth muscles, causing relaxation and increased blood flow in veins, arteries and cardiac tissue.3,12. The above processes lead to decreased work of the heart decreased blood pressure, relief of anginal symptoms, and increased blood flow to the myocardium.3,12,17One in vitro study using mouse aorta suggests that nitric oxide (an activated metabolite of nitroglycerin) targets the natriuretic peptide receptors.7

TargetActionsOrganism
AAtrial natriuretic peptide receptor 1
agonist
Humans
Absorption

Nitroglycerin is rapidly absorbed and is often used in emergency situations for this reason.12 After a sublingual dose of 0.5 mg of nitroglycerin, peak concentration was reached by an average of in 4.4 minutes after administration and was measured to be 2.56 ng/ml.4

Cmax following a 0.6mg dose of sublingual nitroglycerin was measured to be 2.1 ng/mL and AUC was 14.9 minutes, and Tmax was 7.2 minutes.13 Absolute bioavailability after the administration of sublingual nitroglycerin tablets is about 40%. The bioavailability of nitroglycerin depends on factors such as mucosal metabolism and hydration status, which both affect the absorption of sublingual drugs.13

Volume of distribution

The volume of distribution of nitroglycerin is 3 L/kg.16

Protein binding

After a sublingual dose of nitroglycerin, at concentrations in the plasma ranging from 50 to 500 ng/mL, plasma protein binding of nitroglycerin is about 60%. The plasma protein binding of the metabolites 1,2-dinitroglycerin is 60% and that of 1,3-dinitroglycerin is 30%.13

Metabolism

The enzyme mitchochondrial aldehyde dehydrogenase is known to cause the bioactivation of nitroglycerin. Nitroglycerin is metabolized to nitrite, 1,2-glyceryl dinitrate, and 1,3 glyceryl dinitrate.8,16 Nitrite is then metabolized to nitric oxide or S-nitrosothiol.8 The 1,2-and 1,3-dinitroglycerols are less potent in strength than nitroglycerin, but they have longer half-lives, explaining some prolonged effects of nitrates. Both dinitrates are subsequently metabolized to mononitrates that are not active on the blood vessels, and to glycerol and carbon dioxide in the final step of metabolism.6,16

Hover over products below to view reaction partners

Route of elimination

Metabolism is the main route by which nitroglycerin is eliminated from the body.13

Half-life

In a pharmacokinetic study, the plasma half-life of intravenously administered nitroglycerin was 2.8 ± 0.9 minutes.5 The FDA label for the intravenous form of nitroglycerin indicates a similar plasma half-life of about 3 minutes.16 A pharmacokinetic study using sublingual nitroglycerin estimated the plasma half-life to be approximately 6 minutes.4 The elimination half-lives of 1,2- and 1,3-dinitroglycerin (metabolites of nitroglycerin)range between 32-26 minutes.13

Clearance

The FDA label for the intravenous form of nitroglycerin estimates clearance to be 1 L/kg/min.16 Apparent clearance after a sublingual dose was measured to be 21.9 L/min in a pharmacokinetic study of 22 patients with ischemic heart disease and angina.4

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

LD50 information The oral LD50 of nitroglycerin in rats is 105 mg/kg and the LD50 of the intravenous form in rats is 23.2 mg/kg.18

Overdose information An overdose of nitroglycerin can lead to a variety of hemodynamic effects. General effects may include vertigo, fever, flushed skin, and diaphoresis. Cardiorespiratory symptoms may include syncope, dyspnea, decreased heart rate, or palpitations. Neurologic manifestations can include paralysis, seizures, coma, and death.16 There are no known antidotes to an overdose of nitroglycerin, and it is not known whether its metabolites can be removed from the circulation.13,16 If hypotension occurs due to an overdose with nitroglycerin, elevate the lower limbs and administer an intravenous infusion of normal saline or other fluids if necessary to maintain central fluid volume.13,16

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololNitroglycerin may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Acemetacin.
AcetaminophenThe risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Nitroglycerin.
Acetylsalicylic acidThe serum concentration of Nitroglycerin can be increased when it is combined with Acetylsalicylic acid.
AlclofenacThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Alclofenac.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroglycerin.
AlfentanilAlfentanil may decrease the antihypertensive activities of Nitroglycerin.
AlfuzosinAlfuzosin may increase the hypotensive activities of Nitroglycerin.
AliskirenNitroglycerin may increase the hypotensive activities of Aliskiren.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid alcohol.

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Product Images
International/Other Brands
Deponit (UCB Pharma) / Dermatrans (Bayer) / Gen-Nitro (Genpharm ULC) / Glytrin (Sanofi-Aventis) / Glytrin Spray (Sanofi-Aventis) / Natispray (Teofarma) / Nitrocap (Orion) / Nitroderm TTS (Novartis) / Nitrolingual Pump Spray (Arbor Pharmaceuticals) / Rectogesic (ProStrakan) / Stangyl / Transderm-Nitro (Novartis) / Tridil / Trimonit (Sanofi-Aventis) / Trinipatch (Paladin) / Triniplas (Novartis) / Trinispray (Sanofi Aventis) / Trinitrin Simplex Laleuf (Sanofi) / Trinitron (Quesada) / Trinitrosan (Merck) / Trintek (Goldshield) / Trocer (Incepta) / Trocer SR (Incepta) / Vasolator (Sanwa Kagaku) / Vasovin (Torrent) / Venitrin (Meda) / Vernies (Parke Davis) / Willlong (Will-Pharma)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
GonitroPowder400 ug/1SublingualEspero Pharmaceuticals, Inc.2016-07-01Not applicableUS flag
GonitroPowder400 ug/1SublingualAllegis Pharmaceuticals, Inc.2019-07-01Not applicableUS flag
MinitranPatch0.4 mgTransdermalValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada flag
MinitranPatch0.6 mgTransdermalValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada flag
MinitranPatch0.2 mgTransdermalValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada flag
Minitran - Patch Trd 72mg/26.6 Sq CmPatchTransdermalGraceway PharmaceuticalsNot applicableNot applicableCanada flag
Nitro-durPatch40 mg/1TransdermalPhysicians Total Care, Inc.1993-08-132005-12-31US flag
Nitro-durPatch80 mg/1TransdermalIngenus Pharmaceuticals, LLC2017-12-06Not applicableUS flag
Nitro-durPatch120 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-042017-06-02US flag
Nitro-durPatch20 mg/1TransdermalIngenus Pharmaceuticals, LLC2017-12-06Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Apo-nitroglycerinSublingualApotex Corporation2013-09-23Not applicableCanada flag
MinitranPatch18000 ug/1Transdermal3M Company1996-08-302006-12-29US flag
MinitranPatch5 mg/1dTransdermalGraceway Pharmaceuticals2007-04-01Not applicableUS flag
MinitranPatch18 mg/1[USP'U]TransdermalPhysicians Total Care, Inc.2012-02-212012-06-30US flag
MinitranPatch18 mg/1TransdermalBausch Health US, LLC2012-02-21Not applicableUS flag
MinitranPatch54000 ug/1Transdermal3M Company1996-08-302006-12-29US flag
MinitranPatch9000 ug/1Transdermal3M Company1996-08-302006-12-29US flag
MinitranPatch15 mg/1dTransdermalGraceway Pharmaceuticals2007-04-01Not applicableUS flag
MinitranPatch2.5 mg/1dTransdermalGraceway Pharmaceuticals2007-04-01Not applicableUS flag
MinitranPatch54 mg/1TransdermalBausch Health US, LLC2012-02-21Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Nitroglycerin In 5% Dextrose Inj.-100mcg/mlNitroglycerin (10 mg) + Dextrose, unspecified form (5 g)SolutionIntravenousBaxter Laboratories1995-12-312016-02-26Canada flag
Nitroglycerin In 5% Dextrose Inj.-200mcg/mlNitroglycerin (20 mg) + Dextrose, unspecified form (5 g)SolutionIntravenousBaxter Laboratories1995-12-31Not applicableCanada flag
Nitroglycerin In 5% Dextrose Inj.-400mcg/mlNitroglycerin (40 mg) + Dextrose, unspecified form (5 g)SolutionIntravenousBaxter Laboratories1995-12-31Not applicableCanada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Nitro-timeNitroglycerin (9 mg/1)CapsuleOralTIME CAP LABORATORIES, INC2014-06-19Not applicableUS flag
Nitro-TimeNitroglycerin (6.5 mg/1)CapsuleOralAvera McKennan Hospital2015-04-242017-05-24US flag
Nitro-TimeNitroglycerin (2.5 mg/1)CapsuleOralMajor Pharmaceuticals2004-01-292022-10-31US flag
Nitro-TimeNitroglycerin (2.5 mg/1)CapsuleOralCarilion Materials Management2004-01-29Not applicableUS flag
Nitro-TimeNitroglycerin (9.0 mg/1)CapsuleOralMajor Pharmaceuticals2004-01-292022-12-31US flag
Nitro-timeNitroglycerin (6.5 mg/1)CapsuleOralTIME CAP LABORATORIES, INC2014-06-19Not applicableUS flag
Nitro-TimeNitroglycerin (6.5 mg/1)CapsuleOralCarilion Materials Management2004-01-29Not applicableUS flag00904 0644 60 nlmimage10 66353349
Nitro-timeNitroglycerin (2.5 mg/1)CapsuleOralTIME CAP LABORATORIES, INC2014-06-19Not applicableUS flag
Nitro-TimeNitroglycerin (6.5 mg/1)CapsuleOralMajor Pharmaceuticals2004-01-292022-02-28US flag0904 064420180907 15195 1t18elc
NitroglycerinNitroglycerin (9.0 mg/1)CapsuleOralCarilion Materials Management2004-01-29Not applicableUS flag

Categories

ATC Codes
C01DA02 — Glyceryl trinitrateC01DA52 — Glyceryl trinitrate, combinationsC05AE01 — Glyceryl trinitrate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alkyl nitrates. These are organic compounds containing a nitrate that is O-linked to an alkyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organic oxoanionic compounds
Sub Class
Organic nitrates
Direct Parent
Alkyl nitrates
Alternative Parents
Organic nitro compounds / Organic nitric acids and derivatives / Organooxygen compounds / Organic oxides / Organic nitrogen compounds / Hydrocarbon derivatives
Substituents
Aliphatic acyclic compound / Alkyl nitrate / Allyl-type 1,3-dipolar organic compound / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitric acid or derivatives / Organic nitro compound / Organic nitrogen compound / Organic oxide / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
nitroglycerol (CHEBI:28787) / a small molecule (CPD-143)

Chemical Identifiers

UNII
G59M7S0WS3
CAS number
55-63-0
InChI Key
SNIOPGDIGTZGOP-UHFFFAOYSA-N
InChI
InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
IUPAC Name
1,3-bis(nitrooxy)propan-2-yl nitrate
SMILES
[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O

References

Synthesis Reference

Izhak Blank, "Nitroglycerin preparations." U.S. Patent US4482534, issued December, 1979.

US4482534
General References
  1. Ignarro LJ: After 130 years, the molecular mechanism of action of nitroglycerin is revealed. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7816-7. doi: 10.1073/pnas.132271799. [PubMed:12060725]
  2. Chen Z, Zhang J, Stamler JS: Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8306-11. doi: 10.1073/pnas.122225199. Epub 2002 Jun 4. [PubMed:12048254]
  3. Ferreira JC, Mochly-Rosen D: Nitroglycerin use in myocardial infarction patients. Circ J. 2012;76(1):15-21. Epub 2011 Nov 1. [PubMed:22040938]
  4. Blagodatskikh SV, Piotrovskii VK, Metelits VI, Riabokon' OS, Martsevich SIu: [Pharmacokinetics of glycerin trinitrate (nitroglycerin) after sublingual administration in patients with chronic ischemic heart disease]. Farmakol Toksikol. 1987 Nov-Dec;50(6):59-63. [PubMed:3125063]
  5. McNiff EF, Yacobi A, Young-Chang FM, Golden LH, Goldfarb A, Fung HL: Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects. J Pharm Sci. 1981 Sep;70(9):1054-8. [PubMed:6101155]
  6. Cossum PA, Roberts MS, Yong AC, Kilpatrick D: Distribution and metabolism of nitroglycerin and its metabolites in vascular beds of sheep. J Pharmacol Exp Ther. 1986 Jun;237(3):959-66. [PubMed:3086541]
  7. Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ: Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol. 2003 Aug;139(7):1289-96. [PubMed:12890708]
  8. Chen Z, Stamler JS: Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med. 2006 Nov;16(8):259-65. doi: 10.1016/j.tcm.2006.05.001. [PubMed:17055381]
  9. Smith GN, Brien JF: Use of nitroglycerin for uterine relaxation. Obstet Gynecol Surv. 1998 Sep;53(9):559-65. [PubMed:9751938]
  10. Burns SM, Martin M, Merrill P, Luer J, Stone DD: Evaluation and revision of a vasopressin/nitroglycerin protocol for use in variceal bleeding. Am J Crit Care. 1993 May;2(3):202-7. [PubMed:8364671]
  11. Swamy N: Esophageal spasm: clinical and manometric response to nitroglycerine and long acting nitrites. Gastroenterology. 1977 Jan;72(1):23-7. [PubMed:401445]
  12. Kyle H. Kim; Derek J. Schaller (2019). Nitroglycerin. Stat Pearls publishing.
  13. Nitrostat® (Nitroglycerin) FDA Label [Link]
  14. Rectiv FDA label [Link]
  15. FDA Approved Drug Products: Apadaz (benzhydrocodone and acetaminophen) tablets [Link]
  16. Nitroglycerin in Dextrose FDA label [Link]
  17. Nitroglycerin pump spray monograph [Link]
  18. Nitroglycerin MSDS, Pfizer [Link]
  19. MSDS, Nitroglycerin [Link]
  20. Transdermal nitroglycerin [Link]
Human Metabolome Database
HMDB0014865
KEGG Drug
D00515
KEGG Compound
C07455
PubChem Compound
4510
PubChem Substance
46509120
ChemSpider
4354
RxNav
4917
ChEBI
28787
ChEMBL
CHEMBL730
ZINC
ZINC000008214625
Therapeutic Targets Database
DNC001024
PharmGKB
PA450644
PDBe Ligand
TNG
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Nitroglycerin
AHFS Codes
  • 24:12.08 — Nitrates and Nitrites
PDB Entries
4fr8

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentCardiovascular Heart Disease / Chronic Kidney Disease (CKD)1
4CompletedDiagnosticCoronary Artery Disease (CAD)1
4CompletedOtherCardiopulmonary Bypass / Coronary Artery Bypass Grafting (CABG)1
4CompletedPreventionAnginal Pain / Coronary Artery Disease (CAD) / Radial Artery Spasm1
4CompletedPreventionContrast Induced Nephropathy (CIN) / Prophylaxis of Contrast-induced nephropathy1
4CompletedSupportive CareDeliberate Hypotension / Sinus Endoscopic Surgery / Tissue Perfusion1
4CompletedSupportive CareManaging Preterm Labor1
4CompletedTreatmentAcute Heart Failure (AHF)1
4CompletedTreatmentAcute Myocardial Infarction (AMI) / Percutaneous Coronary Intervention (PCI)1
4CompletedTreatmentAngina Pectoris1

Pharmacoeconomics

Manufacturers
  • Novadel pharma inc
  • Pohl boskamp
  • Graceway pharmaceuticals llc
  • Key pharmaceuticals inc sub schering plough corp
  • Hercon laboratories corp
  • Kremers urban co
  • Mylan technologies inc
  • Novartis pharmaceuticals corp
  • G pohl boskamp gmbh and co
  • Sanofi aventis us llc
  • Abraxis pharmaceutical products
  • Hospira inc
  • International medication systems ltd
  • Luitpold pharmaceuticals inc
  • Smith and nephew solopak div smith and nephew
  • Baxter healthcare corp
  • Rorer pharmaceutical corp sub rorer group
  • Parke davis div warner lambert co
  • E fougera div altana inc
  • Pfizer pharmaceuticals ltd
Packagers
  • 3M Health Care
  • Akrimax Pharmaceuticals
  • American Regent
  • A-S Medication Solutions LLC
  • Baxter International Inc.
  • Bradley Pharmaceuticals Inc.
  • Bristol-Myers Squibb Co.
  • C.O. Truxton Inc.
  • Cardinal Health
  • Concord Labs
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • E. Fougera and Co.
  • Eon Labs
  • Ethex Corp.
  • G Pohl Boskamp GmbH and Co. KG
  • Glenmark Generics Ltd.
  • Glenmark Pharmaceuticals
  • Graceway Pharmaceuticals
  • H and H Laboratories
  • Heartland Repack Services LLC
  • Hercon Laboratories Corp.
  • Hospira Inc.
  • Ivax Pharmaceuticals
  • Konec Inc.
  • Lake Erie Medical and Surgical Supply
  • Lohmann Tiererahrung GmbH
  • LTS Lohmann Therapy Systems Corp.
  • Luitpold Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Nippon Kayaku Co. Ltd.
  • North Safety Products
  • Novartis AG
  • Nubenco Enterprises Inc.
  • Nycomed Inc.
  • Pfizer Inc.
  • Pharmedix
  • Physician Partners Ltd.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepak Systems Inc.
  • Qualitest
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sanofi-Aventis Inc.
  • Savage Labs
  • Schering Corp.
  • Schwarz Pharma Inc.
  • Sciele Pharma Inc.
  • Shire Inc.
  • Southwood Pharmaceuticals
  • Summit Pharmaceuticals
  • Time-Cap Labs
  • TriMarc Labs
  • United Research Laboratories Inc.
  • Valsynthese Ltd.
  • Vangard Labs Inc.
  • Vision Pharma LLC
Dosage Forms
FormRouteStrength
OintmentRectal0.4 %
InjectionIntravenous5 MG/ML
PatchTransdermal10 mg/24h
PatchTransdermal5 mg/24h
SolutionIntravenous25 mg
PatchTransdermal10 MG
PatchTransdermal15 MG
PatchTransdermal5 MG
Injection, solutionIntravenous1 mg/ml
InjectionIntravenous1 MG
InjectionIntravenous50 mg/10ml
InjectionIntravenous1 mg/ml
SolutionSublingual400 mcg
PowderSublingual400 ug/1
CapsuleOral7.5 mg
Ointment2 g/100g
PatchTransdermal0.2 mg
PatchTransdermal0.4 mg
PatchTransdermal0.6 mg
PatchTransdermal18 mg/1[USP'U]
PatchTransdermal18 mg/1
PatchTransdermal18000 ug/1
PatchTransdermal36 mg/1
PatchTransdermal36000 ug/1
PatchTransdermal54 mg/1
PatchTransdermal54000 ug/1
PatchTransdermal9 mg/1
PatchTransdermal9000 ug/1
PatchTransdermal
PlasterCutaneous36 mg
Aerosol, meteredSublingual
TabletSublingual0.5 mg
TabletSublingual
CapsuleOral2.5 mg
OintmentTopical20 mg/1g
PatchTransdermal120 mg/1
PatchTransdermal160 mg/1
PatchTransdermal20 mg/1
PatchTransdermal40 mg/1
PatchTransdermal60 mg/1
PatchTransdermal80 mg/1
Injection, solutionIntravenous50 mg/10mL
PlasterCutaneous10 mg
PatchTransdermal50 mg
PatchTransdermal25 mg/24hr
PlasterCutaneous5 mg
PatchTransdermal25 mg
Tablet, extended releaseBuccal
SolutionIntravenous8.518 g
SolutionIntravenous50 mg
Injection, solution, concentrateIntravenous; Parenteral5 MG/1.5ML
Injection, solution, concentrateIntravenous; Parenteral50 MG/50ML
SolutionIntravenous20 mg
Aerosol, meteredSublingual400 ug/1
CapsuleOral9.0 mg/1
Film, extended releaseTransdermal20.8 mg/1
Film, extended releaseTransdermal37.4 mg/1
Injection, solutionIntravenous5 mg/1mL
Injection, solution, concentrateIntravenous5 mg/1mL
PatchTransdermal0.1 mg/1h
PatchTransdermal0.4 mg/1h
PatchTransdermal0.6 mg/1h
TabletOral0.4 mg/1
TabletSublingual0.3 mg/1
TabletSublingual0.6 mg/1
Tablet, orally disintegratingSublingual0.3 mg/1
Tablet, orally disintegratingSublingual0.4 mg/1
Tablet, orally disintegratingSublingual0.6 mg/1
SolutionIntravenous
InjectionIntravenous10 mg/100mL
InjectionIntravenous20 mg/100mL
InjectionIntravenous40 mg/100mL
Injection, solutionIntravenous100 ug/1mL
Injection, solutionIntravenous200 ug/1mL
Injection, solutionIntravenous400 ug/1mL
LiquidIntravenous
CapsuleOral2.5 mg/1
CapsuleOral6.5 mg/1
CapsuleOral9 mg/1
PatchTransdermal10 mg/1d
PatchTransdermal15 mg/1d
PatchTransdermal2.5 mg/1d
PatchTransdermal5 mg/1d
PatchTransdermal0.2 mg/1h
Patch, extended releaseTransdermal0.1 mg/1h
Patch, extended releaseTransdermal0.2 mg/1h
Patch, extended releaseTransdermal0.4 mg/1h
Patch, extended releaseTransdermal0.6 mg/1h
SolutionIntravenous
Capsule, extended releaseOral2.5 MG
Capsule, extended releaseOral5 MG
OintmentTopical
SprayOral400 ug/1
Spray, meteredSublingual400 ug/1
Spray0.4 mg
SprayOral0.4 mg
SprayOral0.41 mg
SpraySublingual0.4 mg
Spray, meteredOral400 ug/1
SpraySublingual400 mcg/1dose
Aerosol, sprayTransmucosal400 ug/1
Injection, solutionIntravenous1 mg/1mL
InjectionIntravenous1 mg/1ml
Tablet, extended releaseOral
Injection, solutionIntravenous25 mg/5mL
TabletOral0.3 mg/1
TabletOral0.6 mg/1
TabletSublingual0.3 mg
TabletSublingual0.4 mg/1
TabletSublingual0.6 mg
InjectionIntravenous10 mg/10ml
OintmentRectal4 mg/1g
OintmentRectal4 mg/g
Patch, extended releaseTransdermal12.5 mg/1
Patch, extended releaseTransdermal25 mg/1
Patch, extended releaseTransdermal50 mg/1
Patch, extended releaseTransdermal75 mg/1
Patch, extended releaseTransdermal
PatchTransdermal15 MG/24h
Injection, solutionIntravenous5 MG/1.5ML
Injection, solutionIntravenous50 MG/50ML
Injection, solution, concentrateIntravenous5 MG/1.5ML
Injection, solution, concentrateIntravenous50 MG/50ML
Tablet, coatedOral0.3 MG
Injection, solutionIntravenous10 mg/10ml
Injection, solution, concentrateIntravenous5 mg
Prices
Unit descriptionCostUnit
Nitrolingual 0.4 mg/spray Solution 12 gm Bottle242.83USD bottle
Nitrolingual 0.4 mg/spray Solution 4.9 gm Bottle141.43USD bottle
Nitro-Dur 30 0.6 mg/hr Patches Box130.86USD box
Nitro-Dur 30 0.8 mg/hr Patches Box130.86USD box
Nitro-Dur 30 0.3 mg/hr Patches Box120.68USD box
Nitro-Dur 30 0.4 mg/hr Patches Box117.1USD box
Minitran 30 0.6 mg/hr Patches Box114.01USD box
Nitro-Dur 30 0.1 mg/hr Patches Box106.09USD box
Nitro-Dur 30 0.2 mg/hr Patches Box105.6USD box
Minitran 30 0.4 mg/hr Patches Box105.18USD box
Minitran 30 0.2 mg/hr Patches Box93.86USD box
Minitran 30 0.1 mg/hr Patches Box92.36USD box
Nitroglycerin 30 0.6 mg/hr Patches Box63.55USD box
Nitroglycerin 5 mg/ml kit62.38USD kit
Nitroglycerin 30 0.4 mg/hr Patches Box57.62USD box
Nitroglycerin 30 0.2 mg/hr Patches Box50.44USD box
Nitrostat 100 0.4 mg Sublingual Tabs Bottle29.88USD bottle
Nitromist 400 mcg spray28.5USD g
Nitrostat 100 0.3 mg Sublingual Tabs Bottle27.75USD bottle
Nitrostat 100 0.6 mg Sublingual Tabs Bottle24.99USD bottle
Nitroglycerin 100 0.6 mg Sublingual Tabs Bottle23.99USD bottle
Nitroglycerin 100 0.3 mg Sublingual Tabs Bottle22.99USD bottle
Nitrostat 25 0.4 mg Sublingual Tabs Bottle19.31USD bottle
Nitroglycerin 25 0.4 mg Sublingual Tabs Bottle9.5USD bottle
Nitro-dur 0.6 mg/hr patch4.19USD patch
Nitro-dur 0.8 mg/hr patch4.19USD patch
Nitro-dur 0.3 mg/hr patch3.87USD patch
Nitro-dur 0.4 mg/hr patch3.87USD patch
Minitran 0.6 mg/hr patch3.51USD patch
Nitro-dur 0.2 mg/hr patch3.45USD patch
Nitro-dur 0.1 mg/hr patch3.4USD patch
Minitran 0.4 mg/hr patch3.24USD patch
Minitran 0.2 mg/hr patch2.89USD patch
Minitran 0.1 mg/hr patch2.84USD patch
Nitroglycerin CR 6.5 mg capsule1.66USD capsule
Nitroglycerin 0.1 mg/hr Patches1.64USD patch
Nitroglycerin CR 9 mg capsule1.27USD capsule
Nitro-Dur 0.8 0.8 mg/hr Patch1.16USD patch
Nitroglycerin er 9 mg capsule1.0USD capsule
Transderm-Nitro 0.4 0.4 mg/hr Patch0.81USD patch
Transderm-Nitro 0.6 0.6 mg/hr Patch0.81USD patch
Minitran 0.4 0.4 mg/hr Patch0.74USD patch
Minitran 0.6 0.6 mg/hr Patch0.74USD patch
Nitroglycerin er 6.5 mg capsule0.72USD capsule
Transderm-Nitro 0.2 0.2 mg/hr Patch0.71USD patch
Nitro-Dur 0.4 0.4 mg/hr Patch0.67USD patch
Nitro-Dur 0.6 0.6 mg/hr Patch0.67USD patch
Trinipatch 0.4 0.4 mg/hr Patch0.67USD patch
Trinipatch 0.6 0.6 mg/hr Patch0.67USD patch
Minitran 0.2 0.2 mg/hr Patch0.66USD patch
Nitrol 2 % Ointment0.64USD g
Nitro-Dur 0.2 0.2 mg/hr Patch0.59USD patch
Trinipatch 0.2 0.2 mg/hr Patch0.59USD patch
Nitroglycerin 9 mg capsule sa0.53USD capsule
Nitro-bid 2% ointment0.48USD g
Nitroglycerin CR 2.5 mg capsule0.47USD capsule
Nitro-time er 9 mg capsule0.37USD capsule
Nitroglycerin 0.4 mg tablet sl0.36USD tablet
Nitrostat 0.4 mg tablet sl0.35USD tablet
Nitro-time er 6.5 mg capsule0.33USD capsule
Nitro-time er 2.5 mg capsule0.29USD capsule
Nitroglycerin er 2.5 mg capsule0.28USD capsule
Nitroglycerin 6.5 mg capsule sa0.22USD capsule
Nitroquick 0.3 mg tablet sl0.19USD tablet
Nitroglycerin 2.5 mg capsule sa0.18USD capsule
Nitroglycerin 2% ointment0.17USD g
Nitrostat 0.6 mg tablet sl0.16USD tablet
Nitroglycerin 0.3 mg tablet sl0.14USD tablet
Nitroglycerin 0.6 mg tablet sl0.14USD tablet
Nitrostat 0.3 mg Sublingual Tablet0.13USD tablet
Nitrostat 0.6 mg Sublingual Tablet0.13USD tablet
Nitrolingual Pumpspray 0.4 mg/dose Metered Dose Spray0.08USD dose
Nitroquick 0.4 mg tablet sl0.08USD tablet
Nitroquick 0.6 mg tablet sl0.08USD tablet
Nitrostat 0.3 mg tablet sl0.07USD tablet
Mylan-Nitro 0.4 mg/dose Metered Dose Spray0.04USD dose
Ntg 25 mg/250 ml in d5w0.04USD ml
Rho-Nitro Pumpspray 0.4 mg/dose Metered Dose Spray0.04USD dose
Ntg 50 mg/500 ml in d5w0.02USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5186938No1993-02-162010-02-16US flag
US7872049No2011-01-182028-03-14US flag
US6500456No2002-12-312018-09-16US flag
US5869082No1999-02-092016-04-16US flag
US9101592No2015-08-112032-03-11US flag
Additional Data Available
  • Filed On
    Filed On
    Available for Purchase

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)13.5 http://www.inchem.org/documents/icsc/icsc/eics0186.htm
boiling point (°C)160http://www.inchem.org/documents/icsc/icsc/eics0186.htm
water solubilitypoor solubility in waterhttp://www.inchem.org/documents/icsc/icsc/eics0186.htm
logP1.62http://www.inchem.org/documents/icsc/icsc/eics0186.htm
logS-3http://www.hmdb.ca/metabolites/HMDB0014865
pKa-5.6http://www.hmdb.ca/metabolites/HMDB0014865
Predicted Properties
PropertyValueSource
Water Solubility0.204 mg/mLALOGPS
logP1.25ALOGPS
logP0.26ChemAxon
logS-3ALOGPS
pKa (Strongest Basic)-5.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area157.11 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity37.59 m3·mol-1ChemAxon
Polarizability15.68 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.7613
Blood Brain Barrier+0.9113
Caco-2 permeable-0.5775
P-glycoprotein substrateNon-substrate0.8322
P-glycoprotein inhibitor INon-inhibitor0.671
P-glycoprotein inhibitor IINon-inhibitor0.9005
Renal organic cation transporterNon-inhibitor0.8325
CYP450 2C9 substrateNon-substrate0.8982
CYP450 2D6 substrateNon-substrate0.9022
CYP450 3A4 substrateNon-substrate0.5255
CYP450 1A2 substrateNon-inhibitor0.8022
CYP450 2C9 inhibitorNon-inhibitor0.7789
CYP450 2D6 inhibitorNon-inhibitor0.9106
CYP450 2C19 inhibitorNon-inhibitor0.72
CYP450 3A4 inhibitorNon-inhibitor0.9173
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8638
Ames testAMES toxic0.9107
CarcinogenicityCarcinogens 0.6822
BiodegradationReady biodegradable0.9479
Rat acute toxicity2.9173 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.512
hERG inhibition (predictor II)Non-inhibitor0.9382
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.71 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
Curator comments
This is a possible target of nitroglycerin, supported by an in vitro study.
General Function
Protein kinase activity
Specific Function
Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate ...
Gene Name
NPR1
Uniprot ID
P16066
Uniprot Name
Atrial natriuretic peptide receptor 1
Molecular Weight
118918.11 Da
References
  1. Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ: Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol. 2003 Aug;139(7):1289-96. [PubMed:12890708]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Electron carrier activity
Specific Function
Not Available
Gene Name
ALDH2
Uniprot ID
P05091
Uniprot Name
Aldehyde dehydrogenase, mitochondrial
Molecular Weight
56380.93 Da
References
  1. Badejo AM Jr, Hodnette C, Dhaliwal JS, Casey DB, Pankey E, Murthy SN, Nossaman BD, Hyman AL, Kadowitz PJ: Mitochondrial aldehyde dehydrogenase mediates vasodilator responses of glyceryl trinitrate and sodium nitrite in the pulmonary vascular bed of the rat. Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H819-26. doi: 10.1152/ajpheart.00959.2009. Epub 2010 Jun 11. [PubMed:20543077]
  2. Chen Z, Zhang J, Stamler JS: Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8306-11. doi: 10.1073/pnas.122225199. Epub 2002 Jun 4. [PubMed:12048254]

Drug created on June 13, 2005 07:24 / Updated on October 29, 2020 19:26

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates